JAK2 and Venous thrombosis: Concerning thrombosis, we confirmed the higher rate of arterial and venous events experienced after diagnosis by JAK2 mutated patients when compared with all the others, especially with TN patients; this detrimental effect remained significant in multivariate analysis including age, gender, thrombosis history, presence of cardiovascular risk factors and also cytoreductive and antiplatelet therapy.